Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Telix Pharmaceuticals American Depositary Shares TLX

Alternate Symbol(s):  TLPPF

Healthcare Biotechnology
Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. It operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.


NDAQ:TLX - Post by User

Telix Pharmaceuticals American Depositary Shares
Bullboard Posts
User Avatar Image
(208)
•••
Post by whytestockson Apr 16, 2024 7:15pm
35 Views
Post# 35992683

InvestorNewsBreaks - QSAM Biosciences Inc. (QSAM) Announces

InvestorNewsBreaks - QSAM Biosciences Inc. (QSAM) Announces
NEWS: $TLPPF InvestorNewsBreaks - QSAM Biosciences Inc. (QSAM) Announces Reverse Stock Split Ratio Ahead of MergerQSAM Biosciences (OTCQB: QSAM) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company a...TLPPF - InvestorNewsBreaks - QSAM Biosciences Inc. (QSAM) Announces Reverse Stock Split Ratio Ahead of Merger

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities